|
News For CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ From The Last 14 Days Check below for free stories on CI;WCG;HNT;MOH;UNH;CVH;WLP;AGP;CNC;HS;HUM;AET;MDT;BSX;STJ the last two weeks. |
|
|
| May 24, 2013 |
| 10:04 EDT |  | CNC | On The Fly: Analyst Downgrade Summary
 Subscribe for More Information |
|
| 06:27 EDT | | CNC | Centene downgraded to Market Perform from Outperform at Raymond James
Subscribe for More Information |
|
| May 23, 2013 |
| 14:21 EDT |  | HNT | Health Net confirms selection for Covered California health insurance exchange
Health Net of California, a wholly owned subsidiary of Health Net, confirmed that it has been selected as a Covered California health plan in the Covered California individual health insurance exchange. The selection means Health Net health plans for individuals and their family members will be offered in many areas of the state when Covered California enrollment begins. Covered California is expected to begin enrolling beneficiaries on Oct. 1, 2013, and benefits are expected to become effective Jan. 1, 2014. Collectively, Health Net and Health Net Life bid to be Covered California health plans in 13 of Covered California’s 19 regions, and were accepted in all 13, the company said. |
|
| 14:19 EDT | | MOH | Molina selected to participate in 'Covered California Marketplace'
Subscribe for More Information |
|
| 13:39 EDT |  | HNT, MOH | Health Net, Molina to offer plans on California exchange, LA Times says
Health Net (HNT) and Molina Healthcare (MOH) were two of the health insurers selected to offer plans on the state's healthcare exchange, according to The LA Times. The companies selected agreed to reduce their profit margins to 2%-3%, the newspaper added. The exchange, which is slated to begin operations next year, is mandated by Obamacare. Reference Link |
|
| 05:44 EDT | | STJ | St. Jude Medical study of EnligHTN shows sustained blood pressure reduction
St. Jude Medical announced that the company's EnligHTN Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year. Patients enrolled in the EnligHTN I trial had an average blood pressure of 176 / 96 mmHg and patients were drug-resistant, meaning their blood pressure could not be controlled through medication. At one year, patients treated with the EnligHTN Renal Denervation System experienced an average systolic blood pressure reduction of 27 mmHg points when measured in an office setting. |
|
| 05:40 EDT | | MDT | Medtronic CoreValue system gains CE mark for transcatheter VIV procedures
Subscribe for More Information |
|
| 05:38 EDT | | MDT | Medtronic's In.Pact Falcon yields positive outcomes in small coronary arteries
Subscribe for More Information |
|
| May 22, 2013 |
| 12:22 EDT | | BSX | Boston Scientific says new data shows blood pressure reduction with Vessix
Boston Scientific reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented at the annual EuroPCR Scientific Program in Paris. Interim data highlights include: All patients underwent successful bilateral renal denervation treatment; At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure; No device-related adverse events or procedural renal artery complications were reported; Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available; Demonstrated success in treating various anatomies, including accessory renal arteries; Demonstrated short renal denervation procedural time. |
|
| 10:44 EDT | | BSX | Boston Scientific says Lotus system met primary performance endpoint in trial
Subscribe for More Information |
| |
| 10:12 EDT |  | CNC | Centene management to meet with Lazard Capital
Subscribe for More Information |
|
| 09:35 EDT | | BSX | Boston Scientific says trials show 'exceptional' safety, efficacy data on stents
Boston Scientific reported positive results from two trials evaluating new, innovative drug-eluting stent technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element Stent System were presented at the annual EuroPCR Scientific Program in Paris. The primary investigator for one trial said, "The Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis. In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2%." |
|
| 07:48 EDT | | MDT | FDA Orthopaedic and Rehabilitation Devices Panel to hold a meeting
Subscribe for More Information |
|
| May 21, 2013 |
| 13:02 EDT | | MDT | Medtronic announces CE Mark for CapSureFix Novus
Medtronic announced CE Mark and launch of its CapSureFix Novus 5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. |
|
| 11:49 EDT | | BSX | Boston Scientific data show Bronchial Thermoplasty benefits for up to five years
Subscribe for More Information |
|
| 11:38 EDT |  | MDT | High option volume stocks: KOS MWE HGG SOL MDT
|
|
| 10:00 EDT |  | AET | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 10:00 EDT | | WCG | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Acquity Group (AQ) downgraded to Neutral from Buy at Roth Capital... Beazer Homes (BZH) downgraded to Neutral from Buy at Sterne Agee... CME Group (CME) downgraded to Neutral from Outperform at Macquarie... Carnival (CCL) downgraded to Neutral from Buy at UBS... Coach (COH) downgraded to Equal Weight from Overweight at Morgan Stanley... Deutsche Bank (DB) downgraded to Neutral from Overweight at JPMorgan... First Republic Bank (FRC) downgraded to Hold from Buy at Jefferies... Franklin Resources (BEN) downgraded to Neutral from Outperform at Macquarie... Life Technologies (LIFE) downgraded to Underperform from Outperform at CLSA... Oil States (OIS) downgraded to Neutral from Buy at Sterne Agee... Raymond James (RJF) downgraded to Market Perform from Outperform at Wells Fargo... VF Corp. (VFC) downgraded to Market Perform from Outperform at Wells Fargo... WellCare (WCG) downgraded to Neutral from Buy at Goldman... Huaneng Power (HNP) downgraded to Neutral from Buy at Citigroup... Comerica (CMA) downgraded to Neutral from Buy at DA Davidson... Beazer Homes (BZH) downgraded at Sterne Agee... Oil States (OIS) downgraded at Sterne Agee... eHealth (EHTH) downgraded to Neutral from Buy at Lazard Capital... Carnival (CCL) downgraded to Market Perform from Outperform at Wells Fargo... Warner Chilcott (WCRX) downgraded to Neutral from Positive at Susquehanna. |
|
| 09:25 EDT | | MDT | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 07:19 EDT |  | MDT | Medtronic sees FY14 EPS $3.80-$3.85, consensus $3.84
Sees FY14 revenue growth up 3%-4% on a constant currency basis. |
| |
| 07:17 EDT | | MDT | Medtronic reports Q4 EPS $1.10, consensus $1.03
Subscribe for More Information |
|
| 06:04 EDT | | AET | Aetna reinstated with a Buy at Goldman
Target $68. |
|
| 06:03 EDT | | WCG | WellCare downgraded to Neutral from Buy at Goldman
Subscribe for More Information |
|
| 05:54 EDT | | MDT | Medtronic announces primary results from Global Symplicity Registry
Subscribe for More Information |
|
| 05:51 EDT | | MDT | Medtronic CoreValue ADVANCE study shows low mortality rates
Subscribe for More Information |
|
| 05:48 EDT | | BSX | OrbusNeich seizes Boston Scientific stents as part of patent infringement case
Subscribe for More Information |
|
| May 20, 2013 |
| 16:31 EDT | | WLP | Wellpoint announces organizational realignment
Subscribe for More Information |
|
| 15:22 EDT | | MDT | Notable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Home Depot (HD), consensus 77c; Medtronic (MDT), consensus $1.03; The TJX Companies (TJX), consensus 62c; AutoZone (AZO), consensus $7.23; Best Buy (BBY), consensus 25c; Dick's Sporting Goods (DKS), consensus 48c; Tidewater (TDW), consensus 61c; Saks (SKS), consensus 19c; Rexnord (RXN), consensus 31c; Monro Muffler Brake (MNRO), consensus 25c. |
|
| 11:12 EDT | | STJ | St. Jude Medical to evaluate defibrilator lead related to reported death
Subscribe for More Information |
|
| 09:47 EDT | | HUM | Humana management to meet with JPMorgan
Subscribe for More Information |
| |
| 09:41 EDT | | MDT, BSX | Supreme Court agrees to hear Medtronic-Boston Scientific patent case
Reported by SCOTUSblog live blog of court orders and opinions. |
|
| 07:42 EDT | | UNH | Cohasset Associates to host a conference
National Conference on Managing Electronic Records is being held in Chicago on May 20-22. |
|
| 07:11 EDT | | MDT | Medtronic receives CE mark for 'export advance' aspiration catheter
Subscribe for More Information |
|
| May 16, 2013 |
| 16:13 EDT | | BSX | Vascular Solutions files patent infringement complaint against Boston Scientific
Vascular Solutions (VASC) announced that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (BSX). The complaint alleges that Boston Scientific has infringed three patents owned by Vascular Solutions concerning rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter which received 510(k) clearance in March. Vascular Solutions is seeking an injunction against Boston Scientific prohibiting the manufacture and sale of its Guidezilla catheter as well as damages for lost profits and legal costs. |
|
| 13:32 EDT | | MDT | Medtronic volatility flat into Q4 and outlook
Subscribe for More Information |
|
| 10:10 EDT | | HUM | Quest Diagnostics Humana acquires Concentra's laboratory business
Subscribe for More Information |
|
| 10:03 EDT | | MDT | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 08:05 EDT | | STJ | St. Jude Medical's 3-D vessel reconstruction system approved in Europe
St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform. |
|
| 07:51 EDT |  | BSX | Boston Scientific price target raised to $12 from $9 at JMP Securities
JMP Securities increased its price target on Boston Scientific as the firm believes after speaking with experts that S-ICD devices can be used in 50% of de novo implant cases, up from its previous estimate of 30%. The firm's FY13 and FY14 earnings estimates for the company are well above consensus levels and it reiterates an Outperform rating on the shares. |
|
| 07:28 EDT | | BSX | I/O Central to host a conference
Subscribe for More Information |
| |
| 06:32 EDT | | MDT | Medtronic downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information |
|
| May 15, 2013 |
| 17:36 EDT | | AET | Paulson gives quarterly update on stakes
Subscribe for More Information |
|
| 06:19 EDT | | WLP | Three WellPoint directors resign, Bloomberg reports
Subscribe for More Information |
|
| May 14, 2013 |
| 19:35 EDT | | CI | Cigna shares could climb 20%, Barron's says
Cigna, which is up more than 50% in the past 12 months, may climb another 20% if it trades closer to 12 times earnings, which it has done in the past, says Barron's Weekday Trader. The report cites Don Wordell, manager of the RidgeWorth Mid-Cap Value Equity fund, who says Cigna's story gets better and better as the company shores up its balance sheet with smart acquisitions and the divestiture of non-core businesses. Reference Link |
|
| 15:33 EDT | | BSX | Boston Scientific has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Mike Mahoney on May 17 at 11 am. |
|
| 12:00 EDT | | AET | Aetna forms strategic alliance with Tawuniya
Subscribe for More Information |
|
| 10:01 EDT | | CI | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AVG Technologies (AVG) downgraded to Neutral from Buy at Goldman... Cigna (CI) downgraded to Hold from Buy at Jefferies... Cree (CREE) downgraded to Neutral from Buy at Sterne Agee... Melco Crown (MPEL) downgraded to Neutral from Buy at UBS... SolarCity (SCTY) downgraded to Neutral from Buy at Roth Capital... KB Home (KBH) downgraded to Market Perform from Outperform at Raymond James... Ryland Group (RYL) downgraded to Underperform from Market Perform at Raymond James... Alere (ALR) downgraded to Hold from Buy at Craig-Hallum... Evolution Petroleum (EPM) downgraded to Hold from Buy at MLV Equity... Oil States (OIS) downgraded to Hold from Buy at BB&T... VIVUS (VVUS) downgraded to Neutral from Buy at Lazard Capital. |
|
| 10:01 EDT |  | WLP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:09 EDT | | STJ | St. Jude Medical announces first patient enrolled in EnligHTN III study
Subscribe for More Information |
|
| 07:18 EDT | | WCG | BofA/Merrill to host a conference
2013 Health Care Conference is being held in Las Vegas on May 14-16. |
| |
| 05:45 EDT | | CI | Cigna downgraded to Hold from Buy at Jefferies
Subscribe for More Information |
|
| 05:43 EDT | | WLP | Wellpoint upgraded to Buy from Hold at Jefferies
Subscribe for More Information |
|
| May 13, 2013 |
| 17:51 EDT | | WLP | Wellpoint reaffirms FY13 EPS view of 'at least' $7.75, consensus $7.99
Subscribe for More Information |
|
| 16:09 EDT | | CI | Cigna names Thomas McCarthy CFO to replace Ralph Nicoletti
Subscribe for More Information |
|
|
|
|
|
